[26] Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007[J]. Clin Microbiol Infect, 2011, 17(12):1859-1867.
[27] Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus[J]. Med Mycol, 2006, 44(4):335-342.
[28] Prevoo RL, Starink TM, de Haan P. Primary cutaneous mucormycosis in a healthy young girl. Report of a case caused by Mucor hiemalis Wehmer[J]. J Am Acad Dermatol, 1991, 24(5pt2): 882-885.
[29] de Oliveira-Neto MP, Da Silva M, Fialho Monteiro PC, et al. Cutaneous mucormycosis in a young, immunocompetent girl. Med Mycol, 2006, 44(6):567-570.
[30] Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)[J]. Clin Microbiol Infect, 2012, 18(10): E396-400.
[31] Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection[J]. Eur J Clin Microbiol Infect Dis, 2006, 25(4):215-229.
[32] Lamaris GA, Ben-Ami R, Lewis RE, et al. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.[J]. J Infect Dis, 2009, 199(9):1399-1406.
[33] Lewis RE, Liao G, Wang W, et al. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection[J]. Virulence, 2011, 2(4):348-355.
[34] Schlemmer F, Lagrange-Xélot M, Lacroix C, et al. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation[J]. Bone Marrow Transplant, 2008, 42(8):551-552.
[35] Lekakis LJ, Lawson A, Prante J, et al. Fatal Rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature[J]. Biol Blood Marrow Transplant, 2009, 15(8): 991-995.
[36] Mousset S, Bug G, Heinz WJ, et al. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation[J]. Transpl Infect Dis, 2010, 12(3):261-264.
[37] Winston DJ, Bartoni K, Territo MC, et al. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients[J]. Biol Blood Marrow Transplant, 2011, 17(4):507-515.
[38] Spreghini E, Orlando F, Giannini D, et al. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility[J]. J Antimicrob Chemother, 2010, 65(10): 2158-2163.
[39] Alastruey-Izquierdo A, Castelli MV, Cuesta I, et al. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers[J]. Antimicrob Agents Chemother, 2009, 53(4):1686-1689.
[40] Alastruey-Izquierdo A, Cuesta I, Walther G, et al. Antifungal susceptibility profile of human-pathogenic species of Lichtheimia[J]. Antimicrob Agents Chemother, 2010, 54(7):3058-3060.
[41] Galgóczy L, Lukács G, Nyilasi I, et al. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes[J]. Acta Biol Hung, 2010, 61(3):356-365.
[42] Vitale RG, de Hoog GS, Schwarz P, et al. Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales[J]. J Clin Microbiol, 2012, 50(1): 66-75.
[43] Alastruey-Izquierdo A, Castelli MV, Cuesta I, et al. In vitro activity of antifungals against Zygomycetes[J]. Clin Microbiol Infect, 2009, 15(S5):71-76.
[44] Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)[J]. Haematologica, 2012, Sep 14.[Epub ahead of print]
[45] Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis[J]. Antimicrob Agents Chemother, 2005, 49(2):721-727.
[46] Argimón S, Galello F, Pereyra E, et al. Mucor rouxii Rho1 protein; characterization and possible role in polarized growth[J]. Antonie Van Leeuwenhoek,2007, 91(3):237-251.
[47] Spellberg B, Fu Y, Edwards JE Jr, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice[J]. Antimicrob Agents Chemother, 2005, 49(2):830-832.
[48] Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis[J]. Antimicrob Agents Chemother, 2008, 52(4):1556-1558.
[49] Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis[J]. Clin Infect Dis, 2008, 47(3):364-371.
[50] Arikan S, Sancak B, Alp S, et al. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus,and synergy testing for Rhizopus[J]. Med Mycol, 2008, 46(6):567-573.
[51] Ibrahim AS, Gebremariam T, Schwartz JA, et al. Posaconazole mono-or combination therapy for treatment of murine zygomycosis[J]. Antimicrob Agents Chemother, 2009, 53(2):772-775. |
